US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VERIDIEN CLIMATE ACTION ETF

18.61

+0.0000

Volume:- -

Turnover:- -

Market Cap:4.09M

PE:- -

High:18.61

Open:18.61

Low:18.61

Close:18.61

Loading ...

Overview Company News Filings

Lumos teams with MedPro to expand US reach of FebriDx point-of-care respiratory test

Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

Press Release: Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Lumos starts ‘pivotal clinical study’ in US for point-of-care respiratory test

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Natera Issues Statement on Guardant Health Litigation

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

Natera Reports Third Quarter 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLIA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLIA\",,,,,undefined,":{"symbol":"CLIA","market":"US","secType":"STK","nameCN":"VERIDIEN CLIMATE ACTION ETF","latestPrice":18.61,"timestamp":1742587200000,"preClose":18.61,"halted":0,"volume":0,"delay":0,"changeRate":0,"change":0,"floatShares":220000,"shares":220000,"lyrEps":0,"amount":0,"amplitude":0,"dividePrice":0.08023,"prevYearClose":20.7542},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLIA\",,,,,undefined,":{"symbol":"CLIA","floatShares":220000,"roa":"--","roe":"--","lyrEps":0,"shares":220000,"dividePrice":0.08023,"high":18.61,"amplitude":0,"preClose":18.61,"low":18.61,"week52Low":16.48,"pbRate":"--","week52High":21.28,"institutionHeld":0,"latestPrice":18.61,"eps":0,"divideRate":0.004311,"volume":0,"delay":0,"ttmEps":0,"open":18.61,"prevYearClose":20.7542},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-19","symbol":"CLIA","reason":null,"defaultRemindTime":1724074200000,"announcedDate":"2024-08-05","type":"delisting","dateTimestamp":1724040000000},{"date":"2023-12-26","symbol":"CLIA","amount":0.080227,"announcedDate":"2023-12-22","type":"dividend","market":"US","newRecordDate":"2023-12-27","defaultRemindTime":1703601000000,"name":"VERIDIEN CLIMATE ACTION ETF","recordDate":"2023-12-28","payableDate":"2023-12-27","currency":"USD","dateTimestamp":1703566800000,"payDate":"2023-12-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLIA\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-26","recordDate":"2023-12-27","paymentDate":"2023-12-28","value":0.080227,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLIA\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503564227","title":"Lumos teams with MedPro to expand US reach of FebriDx point-of-care respiratory test","url":"https://stock-news.laohu8.com/highlight/detail?id=2503564227","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503564227?lang=en_us&edition=fundamental","pubTime":"2025-01-14 10:34","pubTimestamp":1736822094,"startTime":"0","endTime":"0","summary":"Lumos partners with MedPro for national contract sales coverage of FebriDx across hospital and primary care markets in US. FebriDx is a point-of-care diagnostic test to distinguish between bacterial and non-bacterial respiratory infections. Partnership expected to increase awareness and adoption of FebriDx, enhancing its accessibility across the US","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-13-LDX-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-13-LDX-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/lumos-teams-with-medpro-to-expand-us-reach-of-point-of-care-respiratory-test/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["CLIA"],"gpt_icon":0},{"id":"2503451563","title":"Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2503451563","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503451563?lang=en_us&edition=fundamental","pubTime":"2025-01-14 07:49","pubTimestamp":1736812140,"startTime":"0","endTime":"0","summary":"Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing. MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc.  a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes  assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection  testing.\"As the pioneer in multi-cancer early detection, GRAIL is committed to not only evaluating the performance of the Galleri test but also the impact of MCED screen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/patient-reported-outcomes-grails-galleri-234900247.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patient-reported-outcomes-grails-galleri-234900247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLIA","PSA","PRO","BK4533","CSD","BK4217","BK4588","BK4084","GRAL","BK4585","BK4023","BK4139"],"gpt_icon":0},{"id":"2503315523","title":"Press Release: Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2503315523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503315523?lang=en_us&edition=fundamental","pubTime":"2025-01-13 08:20","pubTimestamp":1736727600,"startTime":"0","endTime":"0","summary":"2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook. Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Natera, Inc. , a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following:. Total revenues of approximately $472 million in the fourth quarter of. 2024 compared to $311 million in the fourth quarter of 2023, an increase. Total revenues of approximately $1.7 billion in the full year 2024. compared to $1.1 billion in the full year 2023, an increase of. Approximately 792,800 tests were processed in the fourth quarter of. Approximately 3,064,600 tests were processed in the full year 2024. clinical oncology tests, were processed in the fourth quarter of 2024. tests, in the fourth quart","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU1064131342.USD","BK4585","CLIA","LU2065170008.USD","BK4588","LU0106261612.USD","TM","NTRA","LU2065169927.USD","BK4139","LU2065171402.SGD","LU1988902786.USD","LU0012050646.USD","LU2065731478.USD","LU0053671581.USD","BK4099","LU2065171311.SGD","BK4555","03160"],"gpt_icon":0},{"id":"2492945243","title":"Lumos starts ‘pivotal clinical study’ in US for point-of-care respiratory test","url":"https://stock-news.laohu8.com/highlight/detail?id=2492945243","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492945243?lang=en_us&edition=fundamental","pubTime":"2024-12-20 12:34","pubTimestamp":1734669298,"startTime":"0","endTime":"0","summary":"Lumos begins pivotal FebriDx CLIA waiver study in the US, with the first patient successfully tested. FebriDx is a rapid, point-of-care test to aid in the differentiation between bacterial and non-bacterial acute respiratory infections. Official study commencement triggers first two milestone payments under Lumos’ BARDA partnership, valued at US$925,217","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/2024-12-20-LDX-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/2024-12-20-LDX-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/lumos-starts-pivotal-clinical-study-in-us-for-point-of-care-respiratory-test/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["CLIA"],"gpt_icon":0},{"id":"2492952470","title":"Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics","url":"https://stock-news.laohu8.com/highlight/detail?id=2492952470","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492952470?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":"Amended complaint asserts infringement of U.S. Patent Nos. ‘596 and ‘454 by the modified version of NeoGenomics’ RaDaR assay. AUSTIN, Texas, December 17, 2024----Natera, Inc. , a global leader in cell-free DNA  and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR tests.On December 10, 2024, the District Court for the Middle District of North Carolina  granted Natera’s request to include an additional patent in its ongoing lawsuit against NeoGenomics. Natera’s amended complaint now includes U.S. Patent No. 11,319,596, as well as U.S. Patent No. 11,530,454 as previously asserted in the complaint.Natera asserts infringement of the ’596 and ’454 patents by the new version of NeoGenomics’ RaDaR test, which tests for molecular residual disease. This follows a December 2023 preliminary injunction and September 2024 permanent injunction ordered by the District Court of NeoGenomics’ previous version of its RaDaR test","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LE1exEF9z2DAuShBYmR7Pw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e1233b860341bed9b3f0a480fadc4128","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LE1exEF9z2DAuShBYmR7Pw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e1233b860341bed9b3f0a480fadc4128"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/court-grants-natera-request-additional-130000275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171311.SGD","LU0106261612.USD","LU2065170008.USD","BK4121","LU2065731478.USD","BK4139","LU2065169927.USD","BK4196","LU0053671581.USD","LU2065171402.SGD","NEO","LU0012050646.USD","CLIA","NTRA"],"gpt_icon":0},{"id":"2490385318","title":"Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490385318","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490385318?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:00","pubTimestamp":1734008400,"startTime":"0","endTime":"0","summary":"SAGITTARIUS is Natera's first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancer. Approximately 700-900 patients expected to be enrolled across more than 20 sites. The study aims to enroll approximately 700-900 stage III and high-risk stage II colon cancer patients following surgical resection.SAGITTARIUS includes collaborations with 9 partners in 5 countries in Europe, and a network of 26 clinical centers in Italy, Spain, and Germany.\"The enrollment of the first patients in SAGITTARIUS represents a significant milestone in a trial that has the potential to transform treatment approaches for colorectal cancer,\" said Silvia Marsoni, MD, PhD, head of the precision oncology unit at IFOM ETS and scientific coordinator of the SAGITTARIUS Project.Clara Montagut, MD, PhD, head of the gastrointestinal cancer unit at Hospital del Mar in Barcelona, Spain, and principal investigator of the SAGITTARIUS clinical trial, further emphasized the s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YClgmlG6tPtPBasgJfeoDQ--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eca65d22923dc5978a99654f1eb3daa1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YClgmlG6tPtPBasgJfeoDQ--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eca65d22923dc5978a99654f1eb3daa1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-enrollment-first-patients-130000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065169927.USD","III","LU2065171402.SGD","LU2065171311.SGD","LU2065731478.USD","LU0053671581.USD","BK4134","CLIA","BK4139","LU2065170008.USD","NTRA"],"gpt_icon":0},{"id":"2490727735","title":"Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2490727735","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490727735?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749200,"startTime":"0","endTime":"0","summary":"Cross-ancestry polygenic risk score now offered with the Empower hereditary cancer test. AUSTIN, Texas, December 09, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score  for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer risk, offers individuals who receive a negative test result with Natera’s Empower hereditary cancer test the opportunity for further risk assessment using MyOme’s integrated polygenic risk score.\"We are thrilled to collaborate with Natera to advance MyOme’s vision of predictive healthcare that integrates clinical data with whole genome analysis to develop accurate and personalized risk scores for diseases,\" said Akash Kumar, MD, PhD, chief medical and science officer at MyOme. \"Our integrated PRS score – the first of many clinically impactful ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/F6ddnT4I3qlyg0DY4SYNZw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2462b2a1c144613f2d6d6cc35e163944","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/F6ddnT4I3qlyg0DY4SYNZw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2462b2a1c144613f2d6d6cc35e163944"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-myome-announce-launch-iprs-130000977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","CLIA","BK4139","LU2065169927.USD","LU2065171311.SGD","LU2065731478.USD","NTRA","LU2065170008.USD","LU2065171402.SGD"],"gpt_icon":0},{"id":"2488952328","title":"Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488952328","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488952328?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"Test demonstrated high performance metrics in largest study of its kind in the US with sensitivity of 100% and specificity of 99.3%. AUSTIN, Texas, December 02, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology  published the Company’s clinical validation study on its cell-free DNA  Fetal RhD noninvasive prenatal test .Natera’s study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 655 RhD-negative pregnant patients. The study provides compelling scientific evidence on the ability of Natera’s Fetal RhD NIPT to identify fetal RhD status, and demonstrates its potential to assist patients and clinicians in the prevention and management of RhD alloimmunization. In addition, Natera’s next generation sequencing -based Fetal RhD test can identify RHD pseudogene and other hybrid variants that are more commonly occurring in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0E_FQCipUw5oIeubRQfXlQ--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2ada5b170b1596621eff6cf9fa39ca68","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0E_FQCipUw5oIeubRQfXlQ--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2ada5b170b1596621eff6cf9fa39ca68"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clinical-validation-study-natera-fetal-130000024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMG7P926.USD","D","IE00BMG7P702.HKD","NTRA","IE00BD4GTW91.USD","LU0053671581.USD","IE00BZ18W456.USD","IE00BMG7P694.USD","BK4566","BK4208","CLIA","LU2065169927.USD","IE00BD4GTT62.SGD","IE00B3T34201.USD","LU2065171311.SGD","BK4139","LU2065731478.USD","IE00BZ18W340.USD","BK4588","LU2065171402.SGD","IE00BMQBXF63.USD","BK4585","IE00BD4GTV84.USD","ACOG","IE00BMG7P587.USD","IE00B29SXK94.USD","NGS","BK4179","IE00BMG7P819.SGD","LU2065170008.USD","IE00B29SXL02.USD"],"gpt_icon":0},{"id":"2486873068","title":"Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients","url":"https://stock-news.laohu8.com/highlight/detail?id=2486873068","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486873068?lang=en_us&edition=fundamental","pubTime":"2024-11-27 22:00","pubTimestamp":1732716000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, November 27, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services’  Molecular Diagnostics Services  Program for single lung transplant  recipients. This coverage applies to SLT patients in the surveillance setting.The Prospera test leverages Natera’s core single-nucleotide -based massively multiplexed PCR  technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA  in the recipient’s blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for perf","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zKd4fXYQ.idSN9G22LNuqA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a5413c5334b3d0ebec88d288c771e735","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zKd4fXYQ.idSN9G22LNuqA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a5413c5334b3d0ebec88d288c771e735"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-medicare-coverage-prospera-140000681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4208","LU2065171402.SGD","BK4139","CLAD","BK4588","LU2065169927.USD","LU2065171311.SGD","CLIA","BK4585","LU0053671581.USD","LU2065731478.USD","LU1894683264.USD","BK4189","SLT","LU1894683348.USD","CMS","LU2065170008.USD","NTRA","LU2346227817.USD","LU2637428348.USD","NPV"],"gpt_icon":0},{"id":"2486409663","title":"Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2486409663","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486409663?lang=en_us&edition=fundamental","pubTime":"2024-11-26 08:57","pubTimestamp":1732582620,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, November 26, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium , taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts.\"We are proud to share this new data on Signatera at SABCS that underscores our commitment to generating evidence on the clinical utility of Signatera for patients with breast cancer,\" said Angel Rodriguez, M.D., senior medical director at Natera.The full list of abstracts with selected highlights are as follows:. Clinical Genomics Database ExperiencePoster Spotlight #PS9-01 | Dec. 12 | Presenter: Marla Lipsyc-Sharf, MDActionable Genomic Alterations in Localized Hormone Receptor Positive (HR+) Breast Cancer and Impact on Clinical Outcomes: Results from Comprehensive Whole Exome Sequencing  and Tumor-Informed circulating tumor DNA  analysis. Patient-Reported OutcomesFour ab","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FppRHzChow5e9KF2cJk.pw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/25b490c141d39bec9d23782c9c3ba761","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FppRHzChow5e9KF2cJk.pw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/25b490c141d39bec9d23782c9c3ba761"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-present-signateratm-data-multiple-005700651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4191","BK4590","LU2065171402.SGD","WES","BK4190","LU2065731478.USD","DRFS","LU2065171311.SGD","LU0053671581.USD","LU2065169927.USD","BC","CLIA","BK4139","LU2065170008.USD","NTRA","BK4144"],"gpt_icon":0},{"id":"2486507280","title":"Natera Issues Statement on Guardant Health Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2486507280","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486507280?lang=en_us&edition=fundamental","pubTime":"2024-11-26 04:51","pubTimestamp":1732567860,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, November 25, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today issued the following statement:. In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant’s Reveal test. Today, a jury issued a decision in Guardant’s favor. We disagree with this decision and will ask the Court to overturn it.The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant’s Reveal test. This case had nothing to do with the validity or utility of Signatera, and certain key pieces of evidence supporting Natera’s case were not included in this trial.In the years that have passed since these events, Signatera has become the most widely used MRD test in the U.S., extensively validated with published evidence in more than 100 peer-reviewed papers across multiple cancer types and indicatio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fOdfDzJRZUzc7WoTaYyetw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3627c70a66ad97bff01433b7ef43deb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fOdfDzJRZUzc7WoTaYyetw--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3627c70a66ad97bff01433b7ef43deb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-issues-statement-guardant-health-205100737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171311.SGD","LU2065731478.USD","LU2065170008.USD","CLIA","LU2065169927.USD","LU2065171402.SGD","LU0053671581.USD","NTRA","BK4139"],"gpt_icon":0},{"id":"2486082179","title":"Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2486082179","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486082179?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:00","pubTimestamp":1732543200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, November 25, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that its co-founder and executive chairman, Matthew Rabinowitz, PhD, has been named R&D Leader of the Year by R&D World.Matthew Rabinowitz is co-founder of Natera and currently serves as Executive Chairman of the Company’s board of directors. He served as Natera’s Chief Executive Officer from 2005 to 2019. He also serves as chairman of the board, director or adviser to multiple technology companies and nonprofits involved in diagnostics, biotech, AI and nature conservation; he is on the board of the foundation of the American College of Medical Genetics and invests in a technology fund focused on healthcare. Companies he founded have twice received the World Economic Forum Technology Pioneer awards, given in those years to 20 worldwide, thrice received Edison Awards in the United States, and he has received the Scott Helt Award from IEEE. Dr. Rabinowitz has served as","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7_kQAo23io0GJiIYMfxjtA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e6439a1a80c07898a7ed4de3810d9912","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7_kQAo23io0GJiIYMfxjtA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e6439a1a80c07898a7ed4de3810d9912"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-co-founder-executive-chairman-140000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NTRA","BK4139","LU0053671581.USD","LU2065731478.USD","LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065170008.USD","CLIA"],"gpt_icon":1},{"id":"2485242400","title":"Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM","url":"https://stock-news.laohu8.com/highlight/detail?id=2485242400","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485242400?lang=en_us&edition=fundamental","pubTime":"2024-11-22 06:31","pubTimestamp":1732228260,"startTime":"0","endTime":"0","summary":"Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology. AUSTIN, Texas, November 21, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease  test, Signatera.Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date.In clinical studies, Signatera continues to demonstrate excellent performance, and evidence-based use of Signatera in a real-world setting exemplifies its clinical utility and potential in guiding clinical care. These impactful studies have not only paved the way for coverage across a broad range of cancer type","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tmKkHF.uZkT96JHotxGVEg--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ec2a810c00efaa321a853f4c9fa5ddd7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tmKkHF.uZkT96JHotxGVEg--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ec2a810c00efaa321a853f4c9fa5ddd7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-publication-over-100-223100613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","NTRA","LU2065171311.SGD","LU2065731478.USD","LU0053671581.USD","CLIA","LU2065169927.USD","BK4139","LU2065170008.USD"],"gpt_icon":1},{"id":"2484798955","title":"GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484798955","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484798955?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:01","pubTimestamp":1731963660,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibilitywith the investigational GRAIL Non-Small Cell Lung Cancer  ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca  in collaboration with Daiichi Sankyo .In 2022, GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic  assays for use with AstraZeneca's therapies. GRAIL is committed to leveraging its blood-based methylation testing for patient care by developing fit-for-purpose diagnostics to enable precision oncology strategies with biopharma partne","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H0W_YR0aAlLQ9_M4J5MNSg--~B/aD03Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H0W_YR0aAlLQ9_M4J5MNSg--~B/aD03Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/grail-announces-first-patient-tested-210100573.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grail-announces-first-patient-tested-210100573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLIA","GRAL","BK4139","DSKYF","DSNKY","AZN"],"gpt_icon":0},{"id":"2483050368","title":"Natera Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050368","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483050368?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, November 12, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024.Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period.Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023.Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an increase of 23.9%.Third Quarter Ended September 30, 2024 Financial Results. Natera processed approximately 775,800 tests in the third quarter of 2024, including approximately 760,700 tests accessioned in its laboratory, compared to approximately 626,000 tests processed, including approximately 609,800 tests accessioned in its labora","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M72hPbrqxo6TEojPC3iPsA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/807f17de5c0384515238865145e8b9e4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M72hPbrqxo6TEojPC3iPsA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/807f17de5c0384515238865145e8b9e4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-reports-third-quarter-2024-210500417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171311.SGD","LU2065169927.USD","LU2065731478.USD","BK4139","LU2065171402.SGD","LU2065170008.USD","CLIA","LU0053671581.USD","NTRA"],"gpt_icon":1}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":59}]}}